Many patients fail to reach their lipid treatment goals despite best standard-of-care treatment.1,2 New therapies are needed to address residual cardiovascular risk, particularly in high-risk and very high-risk dyslipidaemia. Ribonucleic acid (RNA)-based therapies developed for genetically validated targets are potentially cost-effective, simple to manufacture and are showing promising results in clinical trials.3 The limbic spoke ...
Emerging RNA-based therapies for management of dyslipidaemias
6 Aug 2021
Sponsored by Novartis Pharmaceuticals Australia Pty Ltd